| A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis |
Mayes |
Astrazeneca |
| Randomized, Double-Blind, Placebo-Controlled Proof-of-Concept Study to Evaluate the Efficacy, Safety and Tolerability of Efzofitimod in Patients With Systemic Sclerosis Related Interstitial Lung Disease |
Mayes |
aTyr Pharma |
| A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with early progressive diffuse cutaneous systemic sclerosis |
Mayes |
Boehringer Ingelheim Pharmaceuticals |
| A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) |
Mayes |
Prometheus Biosciences (now Merck) |
| A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2b Platform Clinical Trial Evaluating the Safety and Efficacy of Investigational Products in Patients with Interstitial Lung Disease Secondary to Systemic Sclerosis (CONQUEST) |
McMahan |
SRF/ Medpace Clinical Research |
| Interrogating the pathophysiological mechanisms of constipation in patients with systemic sclerosis |
McMahan |
NIH |
| Molecular Profiling of Spinal Disease Progression in Ankylosing Spondylitis |
Hwang |
NIH |
| A randomized placebo-controlled, double blind phase 2 clinical trial of memantine for the treatment of cognitive impairment in systemic lupus erythematosus |
Subash |
VUMC Clear Memory |
| A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
Hwang |
Janssen Research & Development |